Literature DB >> 22538173

Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs.

Amanda J Abraham1, Lauren A O'Brien, Hannah K Knudsen, Brian E Bride, G Rush Smith, Paul M Roman.   

Abstract

Racial and ethnic minorities and injection drug users (IDUs) are at increased risk of HIV infection. However, the associations between these caseload characteristics and the availability of onsite HIV testing in substance use disorder treatment programs are unknown. This study uses data collected in 2008-2009 from 198 program administrators of treatment programs participating in the National Institute on Drug Abuse's Clinical Trials Network to address this gap in the literature. Results show positive associations between the percentages of African American, Hispanic, and IDU patients and the odds of offering non-rapid onsite HIV testing versus no onsite testing. The associations between racial/ethnic composition and the availability of rapid HIV testing were more complicated. These findings suggest that many programs are responding to the needs of at-risk populations. However, programs and their patients may benefit from greater adoption of rapid testing which is less costly and better ensures that patients receive their results.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22538173      PMCID: PMC3408854          DOI: 10.1016/j.jsat.2012.03.004

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  35 in total

1.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

2.  Outpatient substance abuse treatment and HIV prevention: an update.

Authors:  Harold A Pollack; Thomas D'Aunno; Barbara Lamar
Journal:  J Subst Abuse Treat       Date:  2006-01

3.  HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005.

Authors:  Harold A Pollack; Thomas D'Aunno
Journal:  J Subst Abuse Treat       Date:  2010-02-19

4.  Co-located substance use treatment and HIV prevention and primary care services, New York State, 1990-2002: a model for effective service delivery to a high-risk population.

Authors:  Jeffrey Rothman; Diane Rudnick; Marc Slifer; Bruce Agins; Karl Heiner; Guthrie Birkhead
Journal:  J Urban Health       Date:  2007-03       Impact factor: 3.671

5.  Enhanced HIV testing, treatment, and support for HIV-infected substance users.

Authors:  Nora D Volkow; Julio Montaner
Journal:  JAMA       Date:  2010-04-14       Impact factor: 56.272

6.  HIV rapid testing in substance abuse treatment: implementation following a clinical trial.

Authors:  L F Haynes; J E Korte; B E Holmes; L Gooden; T Matheson; D J Feaster; J A Leff; L Wilson; L R Metsch; B R Schackman
Journal:  Eval Program Plann       Date:  2011-03-01

7.  Availability of HIV-related health services in adolescent substance abuse treatment programs.

Authors:  H K Knudsen; C B Oser
Journal:  AIDS Care       Date:  2009-10

8.  Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users.

Authors:  F Molitor; S R Truax; J D Ruiz; R K Sun
Journal:  West J Med       Date:  1998-02

9.  HIV/AIDS services in private substance abuse treatment programs.

Authors:  Amanda J Abraham; Lauren A O'Brien; Brian E Bride; Paul M Roman
Journal:  Drug Alcohol Depend       Date:  2010-12-08       Impact factor: 4.492

10.  An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units.

Authors:  T D'Aunno; T E Vaughn; P McElroy
Journal:  J Health Soc Behav       Date:  1999-06
View more
  8 in total

1.  Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.

Authors:  Lydia Aletraris; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2015-04-13

2.  Patterns of Substance Use and Arrest Histories Among Hospitalized HIV Drug Users: A Latent Class Analysis.

Authors:  Karen Shiu-Yee; Ahnalee M Brincks; Daniel J Feaster; Jemima A Frimpong; Ank Nijhawan; Raul N Mandler; Robert Schwartz; Carlos Del Rio; Lisa R Metsch
Journal:  AIDS Behav       Date:  2018-09

3.  HIV rapid testing in drug treatment: comparison across treatment modalities.

Authors:  Robert P Schwartz; Maxine L Stitzer; Daniel J Feaster; P Todd Korthuis; Anika A H Alvanzo; Theresa M Winhusen; Lillian Donnard; Ned Snead; Lisa R Metsch
Journal:  J Subst Abuse Treat       Date:  2012-09-27

4.  Integrating Routine HIV Testing into Family Planning Clinics That Treat Adolescents and Young Adults.

Authors:  Ruth S Buzi; Farrah L Madanay; Peggy B Smith
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

5.  HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations.

Authors:  Thomas D'Aunno; Harold A Pollack; Lan Jiang; Lisa R Metsch; Peter D Friedmann
Journal:  Health Serv Res       Date:  2013-07-16       Impact factor: 3.402

6.  Uptake of HIV testing in substance use disorder treatment programs that offer on-site testing.

Authors:  Tiffany L Kyle; Viviana E Horigian; Susan Tross; Valerie A Gruber; Margaret Pereyra; Raul N Mandler; Daniel J Feaster; Lisa R Metsch
Journal:  AIDS Behav       Date:  2015-03

7.  A mixed methods study of HIV-related services in buprenorphine treatment.

Authors:  Hannah K Knudsen; Jennifer Cook; Michelle R Lofwall; Sharon L Walsh; Jamie L Studts; Jennifer R Havens
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-08-16

8.  On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial.

Authors:  Jemima A Frimpong; Thomas D'Aunno; David C Perlman; Shiela M Strauss; Alissa Mallow; Diana Hernandez; Bruce R Schackman; Daniel J Feaster; Lisa R Metsch
Journal:  Trials       Date:  2016-03-03       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.